CRIS
Curis, Inc.
There isn't enough reported data to score CRIS yet.
CRIS Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Weak | |
| Unavailable |
CRIS's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
CRIS PE Valuation
CRIS has no meaningful PE right now: it lost money over the past year.
CRIS Forward outlook
There aren't enough analyst estimates for CRIS to show an outlook.
CRIS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$2.02 | +$92.58 |
| Q1 2026 | -$11.60 | +$110.00 |
| Q4 2025 | -$11.60 | +$126.00 |
| Q3 2025 | -$70.40 | +$85.80 |
| Q2 2025 | -$94.60 | +$70.20 |
| Q1 2025 | -$121.60 | +$50.60 |
| Q4 2024 | -$137.60 | +$41.60 |
| Q3 2024 | -$156.20 | +$30.40 |
CRIS is still losing money, but far less than before: $2.02 per share over the past year, against $388.00 at its worst in late 2019.
CRIS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $1.1M | -66% |
| Q3 2025 | $3.2M | +8.4% |
| Q2 2025 | $2.7M | +8% |
| Q1 2025 | $2.4M | +14% |
| Q4 2024 | $3.3M | +24% |
| Q3 2024 | $2.9M | +3.5% |
| Q2 2024 | $2.5M | +16% |
| Q1 2024 | $2.1M | -9.2% |
CRIS's revenue has slid since its 2024 peak: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | 1724% | +1993 points |
| Q3 2025 | -218% | +143 points |
| Q2 2025 | -300% | +191 points |
| Q1 2025 | -427% | +171 points |
| Q4 2024 | -269% | +184 points |
| Q3 2024 | -361% | +76 points |
| Q2 2024 | -491% | +61 points |
| Q1 2024 | -598% | -92 points |
CRIS's operating margin was 1724% last quarter, up 1993 points from the same quarter a year ago, near the top of its range since 2019.
CRIS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$9.6M | -$1.6M |
| Q1 2026 | -$9M | -$1.7M |
| Q4 2025 | -$6.4M | +$2.9M |
| Q3 2025 | -$5.6M | +$367K |
| Q2 2025 | -$8M | +$3.1M |
| Q1 2025 | -$7.3M | +$6M |
| Q4 2024 | -$9.3M | +$926K |
| Q3 2024 | -$5.9M | +$2.2M |
CRIS has burned cash in almost every quarter: −$31M over the past year, against −$30M the year before.
CRIS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +121% | +1.2M shares |
| 1 year | +238% | +1.5M shares |
| 3 years | +784% | +1.9M shares |
| 5 years | +1187% | +2M shares |
| Available history | +2473% | +2.1M shares |
CRIS has 2M diluted shares, up 238% from a year ago.
CRIS Net Leverage
CRIS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
CRIS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 23.9 | Oversold |
| Stochastic | 7.6 | Oversold |
CRIS's weekly RSI is 24 (oversold) and its Stochastic is 8 (oversold).
CRIS PE vs Healthcare Sector
CRIS has no meaningful PE right now: it lost money over the past year.
CRIS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.65 | 12% below |
| 20 week MA | $2.20 | 74% below |
| 50 week MA | $10.3 | 94% below |
| 100 week MA | $26.8 | 98% below |
| 200 week MA | $118.4 | 100% below |
CRIS is in a downtrend: it's below all five of its weekly moving averages, and 100% below its 200-week average.
CRIS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $620.0 | $3,180.0 | +413% |
| 2021 | $3,180.0 | $2,072.0 | -35% |
| 2022 | $2,072.0 | $197.4 | -90% |
| 2023 | $197.4 | $255.0 | +29% |
| 2024 | $255.0 | $65.0 | -75% |
| 2025 | $65.0 | $21.2 | -67% |
| 2026 YTD | $21.2 | $0.57 | -97% |
CRIS's yearly returns have swung widely, from +413% in 2020 to −90% in 2022. It's down 97% so far in 2026.